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REVIEW CURRENTOPINION Targeting activated protein C to treat hemophiliawww.co-hematology.com´ a b aStephanie G.I. Polderdijk , Trevor P. Baglin , and James A. HuntingtonPurpose of review
Hemophilia is a debilitating disease, marked by frequent, painful bleeding events, joint deterioration
and early death. All current treatments consist of i.v. infusions of replacement factor or other
procoagulant factors, and are incompletely effective, due in part to the short half-lives of the proteins.
An alternative approach is to rebalance hemostasis by inhibiting natural anticoagulant mechanisms.
In this article, we explain why activated protein C (APC) is an appropriate and safe target for the
treatment of hemophilia.
Recent findings
A serpin (serine protease inhibitor) was engineered to specifically inhibit APC and was found to rescue
hemostasis in a hemophilia mouse model, even after a severe tail clip injury. However, APC is also anti-
inflammatory and has cytoprotective activities, raising safety concerns over the use of an APC inhibitor to
treat hemophilia. We summarize the molecular basis of the anticoagulant and signaling activities of APC to
assess the potential impact of targeting APC.
Summary
We conclude that the signaling and anticoagulant functions of APC are in spatially and kinetically distinct
compartments, and that it is possible to specifically inhibit the anticoagulant activity of APC. Targeting APC
with a serpin is remarkably effective and may be safe for long-term prophylactic use in the treatment of
hemophilia.
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Hemostasis is a dynamic process involving procoa-
gulant and anticoagulant factors operating simul-
taneously to detect and repair damage to the
vascular endothelium, and to prevent inappropri-
ate clot formation (Fig. 1). Perturbations affecting
this balance cause bleeding or thrombosis, because
of insufficient or excessive formation of the enzyme
thrombin. Hemophilia is a debilitating bleeding
disorder caused by deficiency or defects in factor
(f) VIII (hemophilia A) or fIX (hemophilia B).
Treatment usually consists of prophylactic or on-
demand infusions of the missing factor, but a frac-
tion of patients develop inhibitory antibodies and
require the use of ‘bypassing’ agents. Both replace-
ment and bypassing treatments work by bolstering
procoagulant forces, but rebalancing can also be
achieved by suppression of anticoagulants. In this
review, we describe our reasons for targeting
activated protein C (APC) to rebalance hemostasis
in hemophilia; the remarkable efficacy of an engin-
eered APC-specific inhibitor; and how compart-
mentalization of APC activities should allay
concerns over safety.THE RATIONALE FOR TARGETING
ACTIVATED PROTEIN C IN HEMOPHILIA
APC is activated from its precursor zymogen protein
C by thrombin bound to the cofactor thrombomo-
dulin on the surface of endothelial cells [1]. This
event is accelerated 20-fold by the binding of
protein C to the same cell surface via an interaction
between its g-carboxyglutamic acid (Gla) domainVolume 24  Number 5  September 2017
KEY POINTS
 APC is a powerful anticoagulant that limits
thrombin production.
 Inhibition of APC restores normal hemostasis in
hemophilia models.
 The anti-inflammatory and cytoprotective activities
attributed to APC are distinct from its anticoagulant
function.
 APC can be safely targeted to treat hemophilia.
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(Fig. 2). Once formed, APC exerts its anticoagulant
activity by proteolytically inactivating the cofactorsFIGURE 2. APC generation and signaling on endothelial cells.
Thrombin (IIa) activates protein C (PC) after binding to
thrombomodulin (TM) on endothelial cells (blue lipid bilayer).
Thrombin interacts with TM via EGF-like domains 5 and 6,
sometimes with the aid of chondroitin sulfate (hexagons).
PC binds to endothelial protein C receptor (EPCR) via its
Gla domain (green circle), thereby approximating PC to
thrombin. Once formed, APC can cleave PAR1 to elicit anti-
inflammatory and cytoprotective effects. However, APC
dissociates rapidly and is replaced by the more abundant PC.
APC, activated protein C; PAR1, protease activated receptor-1.
FIGURE 1. Schematic of the hemostatic network and the
major endogenous anticoagulants. Stable hemostatic clots are
formed by the action of thrombin on platelets and fibrinogen.
Too little thrombin leads to bleeding and too much thrombin
causes thrombosis. Clotting is initiated by the extrinsic Xase
complex (TF-fVIIa) on subendothelial cells, rapidly producing
fXa to feed the prothrombinase complex (fXa-fVa). The
extrinsic Xase complex is inhibited by TFPI, and further fXa
generation relies on the intrinsic Xase complex (fIXa-fVIIIa,
deficient in hemophilia). The serpin antithrombin (AT) inhibits
fXa and thrombin, and APC breaks down the intrinsic Xase
and prothrombinase complexes. Treating hemophilia aims to
improve thrombin generation by either replacing the missing
factor or augmenting the concentration of other clotting
factors. Alternative strategies include inhibition of TFPI and
APC, or lowering the concentration of AT. TF, tissue factor;
TFPI, tissue factor pathway inhibitor.
1065-6251 Copyright  2017 The Author(s). Published by Wolters Kluweof the intrinsic Xase (fVIIIa) and prothrombinase
(fVa) complexes (Fig. 1). Its potency is well estab-
lished, but was recently demonstrated anew in a
family with an unexplained bleeding disorder [3].
We found a c.1611C>A mutation in the thrombo-
modulin gene (p.Cys537Stop), causing a truncation
within the C-terminal transmembrane helix and
resulting in highly elevated plasma levels of soluble
thrombomodulin. The elevation in circulating
thrombomodulin caused systemic protein C acti-
vation, and resulted in trauma-induced and some
spontaneous bleeding in affected family members.
However, one carrier of the thrombomodulin
mutation had no history of bleeding, and sequenc-
ing revealed that he was also a carrier of the fVLeiden
mutation, which causes APC resistance.
The Leiden mutation, c.1691G>A (Arg506Gln),
is present in 5% of whites and is the most common
cause of thrombophilia [4]. The mutation is at the
primary APC cleavage site in fVa and confers partial
APC resistance by slowing the rate of inactivation by
seven-fold (three-fold when the cofactor protein S is
present) [5]. It is sufficiently common that fVLeiden
has been found coincidentally in hemophiliar Health, Inc. www.co-hematology.com 447
Hemostasis and thrombosispatients, and in some cases the bleeding severity
appears milder than what would be expected based
solely on factor levels (for review, see [6]). These
clinical observationswere supported by the rescue of
hemostasis in hemophilia mice crossed with fVLeiden
mice; however, the effect appeared to be limited to
small vessels [7]. The magnitude of the effect of
fVLeiden in ameliorating the clinical manifestations
of hemophilia is somewhat controversial. However,
observations are limited to fVLeiden heterozygotes in
whom half of the fVa generated will be inactivated
by APC at the normal rate, and half at a rate only
3–7-fold slower. Overall, the data suggest that if fVa
can be protected from degradation by APC, normal
hemostasis can occur in the absence of the intrinsic
Xase complex (i.e. in hemophilia).AN ACTIVATED PROTEIN C-SPECIFIC
SERPIN NORMALIZES BLEEDING IN
HEMOPHILIA MODELS
APC is a trypsin-like serine protease, and its princi-
pal physiological inhibitor is the serpin (serine pro-
tease inhibitor) protein C inhibitor (PCI). However,
PCI is highly promiscuous and is a better inhibitor of
procoagulant proteases, such as thrombin, fXa, fXIa,
fVIIa-TF, than of the anticoagulant APC [8]. Indeed,
adding PCI to plasma to a final concentration of
5mM extends the activated partial thromboplastin
time (aPTT) from 1 min to unclottable after 5 min
[9]. The challenge, therefore, was to alter the speci-
ficity of PCI so as to reduce the inhibition of
procoagulant proteases while maintaining or
improving inhibition of APC. The serpin mechan-
ism of protease inhibition is well established
(Fig. 3a) [10], and the principal determinant of
serpin specificity is the amino acid composition of
the reactive center loop (RCL). The RCL of the serpin
acts as a pseudo-substrate for serine proteases by
forming a recognition complex before hydrolysis
begins. In the commonly used nomenclature, the
bond that is targeted by a protease is between the P1
and P1’ residues, and amino acids to either side are
numbered sequentially (with a ’ toward the C-ter-
minus). Proteases typically utilize the sequences
from P4 to P3’ to recognize their substrates, with
specificity primarily determined by the residue at
the P1 position. All clotting proteases, including
APC, require a P1 arginine in their substrates, so
to confer our desired specificity profile we mutated
residues on either side of P1, guided by published
structures of thrombin and APC [11
&
] (Fig. 3b).
The active sites of thrombin and APC were most
different at the S2 and S1’ sites (where P2 and P1’
side chains fit), with APC predicted to be more
accommodating of large positively charged side448 www.co-hematology.comchains. We found that mutating P2 and P1’ to lysine
conferred a high degree of specificity for APC over
thrombin, and when the mutated PCI was added to
plasma at 5mM the aPTT was unaffected. However,
the mutated PCI was not an attractive drug candi-
date because of its low rate of APC inhibition
(280M1 s1, a two-fold reduction relative to wild-
type) and short half-life (24h).
We therefore decided to switch the template
serpin to a1-antitrypsin (a1AT) which has a
5–7 day half-life. The P1 Arg ‘Pittsburgh’ variant
has been reported in several people, most of whom
had associated bleeding due to the change in speci-
ficity fromneutrophil elastase to coagulation factors
[12,13]. The Pittsburgh variant of a1AT also happens
to be an excellent inhibitor of APC, with a rate
constant of 1105M1 s1. When the flanking
Lys mutations were made at the P2 and P1’ pos-
itions, a similar gain in specificity was obtained with
no increase in aPTT observed when spiked into
plasma. Importantly, when the mutated a1AT (Ser-
pinPC) was added to normal or hemophilia plasma
(in the presence of thrombomodulin to activate the
protein C system), it rescued thrombin generation
in a dose-dependent manner. The effect of SerpinPC
on hemostasis was assessed in a hemophilia mouse
model, monitoring clot formation by intravital
microscopy after laser-induced injury and blood
loss after tail clip. With both challenges, we
observed correction of hemostasis. These results
demonstrated that inhibition of the protein C anti-
coagulant pathway by an APC-specific serpin is
effective at restoring hemostasis in vivo in the
absence of the intrinsic Xase complex, and may
be useful in the treatment of hemophilia.ACTIVATED PROTEIN C SIGNALING IS
DEPENDENT ON ENDOTHELIAL PROTEIN C
RECEPTOR AND PROTEASE ACTIVATED
RECEPTOR-1
In addition to its anticoagulant function, APC also
exerts important anti-inflammatory, antiprolifera-
tive and cytoprotective activities that have been
demonstrated in vitro and in animal models. Indeed,
recombinant APC was approved as a treatment for
sepsis (marketedbyEli Lilly asXigris), although itwas
later withdrawn after a placebo-controlled clinical
trial (PROWESS-SHOCK) failed to demonstrate
efficacy [14]. It is therefore important to consider
whether inhibition of APC might have unwanted
proinflammatory effects by reviewingwhat is known
about how APC exerts its signaling activities.
As mentioned above, EPCR binding to protein C
accelerates the formation of APC, thereby exerting
an anticoagulant function. However, EPCR isVolume 24  Number 5  September 2017
FIGURE 3. The serpin mechanism of protease inhibition requires reactive center loop accommodation into the protease active
site. (a) Native serpins are composed of two major features required for protease inhibition, b-sheet A (red) and the reactive
center loop (RCL, yellow). Inhibition of a protease (magenta) depends on recognition of the P1 residue (sticks) and surrounding
RCL residues as a substrate (middle). At the acyl-enzyme stage of hydrolysis, the covalently attached protease is flung to the
opposite pole of the serpin through incorporation of the RCL into b-sheet A (right). (b) The structures of thrombin (left) and APC
are shown in the standard orientation with their surfaces colored according to electrostatics (red negative, blue positive). The
subsites that interact with the P2, P1 and P1’ residues of a serpin (S, indicated) are different between the two proteases. This
was exploited by engineering a serpin with Lys-Arg-Lys sequence (yellow sticks) to confer specificity for APC over thrombin.
APC, activated protein C.
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attributed to APC, by localizing APC to the
endothelial cell surface where it can cleave and
activate the G-protein coupled receptor, protease
activated receptor 1 (PAR-1) (Fig. 2). The depend-
ence of APC signaling on both EPCR and PAR-1 was
shown in vitro [15] and in mouse models [16]. APC
cleavage of PAR-1 produces anti-inflammatory and
cytoprotective effect, but paradoxically thrombin
cleavage of PAR-1 (25000-times faster than APC)
has proinflammatory, proapoptotic effects and
reduces endothelial barrier function (reviewed in
[17]). Since thrombin, as the protein C activator,1065-6251 Copyright  2017 The Author(s). Published by Wolters Kluweis necessarily present at the time APC is formed on
endothelial cells, it is unclear which PAR-1 signaling
pathway is dominant with endogenous proteins in
the normal physiological setting. This issue was
partially resolved by some recent studies by Ray
Rezaie’s group, demonstrating that occupancy of
EPCR by protein C or APC is sufficient to elicit
protective signaling, even if cleavage of PAR-1 is
mediated by thrombin [18,19,20
&&
]. It was con-
cluded that in the physiological setting where EPCR
is occupied by protein C or APC, PAR-1 cleavage by
either thrombin or APC will elicit anti-inflamma-
tory and cytoprotective effects.r Health, Inc. www.co-hematology.com 449
Hemostasis and thrombosisPROTEIN C DEFICIENCY
Protein C deficiency in humans is associated with a
10-fold increase in risk of early and recurrent venous
thrombosis, and homozygous deficiency causes
neonatal purpura fulminans, a life-threatening con-
dition characterized by microvascular thrombosis.
Similar effects are seen in animal models, with full
deficiency in mice leading to neonatal death caused
by disseminated intravascular coagulation (DIC)
[21]. The importance of the protein C levels in
thrombosis is therefore well established. To investi-
gate the importance of endogenous protein C in
inflammation, partial knockout mice were made
with levels ranging from 1 to 18% of normal
[22,23]. Mice with levels below 3% were prone to
DIC, similar to complete knockouts. Surviving mice
with low protein C levels were found to be highly
susceptible to lipopolysaccharide (LPS) challenge,
exhibiting increased inflammatory markers and
signs of DIC. In contrast, mice with levels approxi-
mately 18% of normal were protected from low-
dose LPS challenge. It is interesting to note that
warfarin treatment typically reduces the amount
of correctly processed Gla domain to about 20%
for vitamin K-dependent coagulation factors,
including protein C, and its use has not been associ-
ated with any inflammatory disease.SELECTIVE INHIBITON OF ACTIVATED
PROTEIN C ACTIVITIES
To investigate the relative importance of the anti-
coagulant and anti-inflammatory effects of protein
C/APC in mice, anti-APC monoclonal antibodies
were generated by the Esmon group [24].
MAPC1591 was found to bind specifically to APC
over protein C and inhibit only its anticoagulant
function, presumably by sterically interfering with
binding to its substrate fVa. MAPC1591 did not,
however, inhibit endothelial cell binding, consist-
ent with an epitope on the catalytic domain of APC.
In contrast, MPC1609 did not distinguish between
protein C and APC, and completely blocked binding
to endothelial cells, suggesting an epitope on the
Gla domain. Both antibodies inhibited the antico-
agulant activity of APC in a one-stage coagulation
assay. However, only MPC1609 blocked the cyto-
protective effect of APC in vitro, consistent with
previous studies showing the dependence of EPCR
binding for APC signaling. These antibodies were
then given to mice at a dose of 10mg/kg, followed
by administration of a sublethal dose of LPS. All
MPC1609-treated mice died within a 3-day window,
whereas all of the MAPC1591 and vehicle-treated
mice survived. Serum interlukin-6 (IL-6) and kidney
function markers [blood urea nitrogen (BUN) and450 www.co-hematology.comcreatinine] were elevated with MPC1609 treatment,
whereas none were elevated in MAPC1591-treated
group. Indeed, IL-6, creatinine and BUN levels were
even lower in the MAPC1591 group than vehicle-
treated controls, indicating a possible protective
effect of inhibiting the anticoagulant activity of
APC in this model. Thrombin-antithrombin com-
plex levels were higher than control in the
MAPC1591-treated animals, confirming effective
inhibition of APC anticoagulant activity. Similar
results were obtained with these antibodies in
mouse models of gram-negative pneumosepsis
[25] and renal ischemia reperfusion injury [26
&
].
The conclusion from these studies was that the
anticoagulant function of endogenous APC is not
required for its anti-inflammatory or cytoprotective
activities. Treatment of hemophilia by inhibiting
APC should therefore be safe, provided that the
inhibitor selectively targets its anticoagulant func-
tion.COMPARTMENTALIZATION OF
ACTIVATED PROTEIN C ACTIVITIES
The signaling activities of APC are dependent on
binding to EPCR on endothelial cells, and the anti-
coagulant activity of APC requires release from EPCR
and diffusion to the site where clotting is occurring.
If PAR-1 cleavage by APC (and not thrombin) is
essential for its signaling activities, administration
of an APC inhibitor would, in theory, inhibit both
its anticoagulant and anti-inflammatory functions.
However, provided that APC inhibition is slower
than its release from EPCR on which it was formed,
then only its anticoagulant function can be affected.
Protein C and APC bind to EPCR with identical
affinity (Kd of 30nM) [27], and as protein C cir-
culates at a higher concentration than APC (70nM
vs. 40pM) [28], once APC dissociates from EPCR it
will not reassociate, limiting its activity to antico-
agulation. So, we can think of APC as existing in two
compartments: the EPCR-bound signaling pool and
the circulating anticoagulant pool. The key to ensur-
ing selective inhibition of the anticoagulant pool of
APC is to tailor the rate of inhibition so that it is
slower than the rate of dissociation from EPCR. The
dissociation rate of APC from EPCR is reported to be
0.09 s1 [29], giving newly formed APC a residence
half-life of less than 8 s. SerpinPC inhibits APC with
a second-order rate constant of approximately
15000M1 s1, and would require a concentration
of 5mM (equivalent to a dose of more than 10mg/
kg) to achieve a t1/2 of inhibition of 8 s. Therefore,
provided that efficacy can be demonstrated in
hemophilia at doses below 10mg/kg, there should
be no effect on APC-mediated signaling. The LPSVolume 24  Number 5  September 2017
Targeting activated protein C to treat hemophilia Polderdijk et al.studies using MAPC1591 were conducted at a dose
of 10mg/kg (about 1mM peak concentration), and
antibodies typically bind their targets with rate con-
stants of approximately 105M1 s1, which trans-
lates to a t1/2 of inhibition of 7 s. Itmay, therefore, be
possible to safely exceed doses of an inhibitor that
would theoretically inhibit APC before it dissociates
from EPCR. This makes sense because cleavage of
PAR1 must occur faster than dissociation of APC
from EPCR. Indeed, a dose of 20mg/kg MAPC1591
was ‘safe’ in the renal ischemia reperfusion model
[26
&
]. On the basis of studies from the Rezaie
group, it is also possible that inhibition of the
proteolytic activity of APC will have no effect on
signaling, even at infinitely high doses of an inhibi-
tor, as protective signaling can be achieved by
thrombin cleavage of PAR-1 so long as protein
C/APC is bound to EPCR.CONCLUSION
Hemophilia treatment has remained essentially
unchanged for over 100 years; blood transfusions
became plasma infusions became factor infusions.
Safety was greatly improved with the introduction
of recombinant factors, but efficacy was still limited
by short half-lives. Recently, there has been a surge
in innovation in the hemophilia space, including
gene therapy, an fVIIIa-mimicking bispecific anti-
body, a small interfering RNA molecule against
antithrombin and antibodies against tissue-factor
pathway inhibitor. The latter two approaches aim
to rebalance hemostasis by reducing intrinsic anti-
coagulant activity. Why then has no APC inhibitor
been developed? One explanation is the fear of
affecting its anti-inflammatory activities. Itmay also
have been unclear how effective an APC-inhibitor
would be in treating hemophilia, as reports of amel-
ioration of clinical severity with coinheritance of
fVLeiden are mixed, and in mouse models fVLeiden
only partially rescues hemostasis. We created an
APC-specific serpin (SerpinPC) and found that it
rescued hemostasis in an intravital microscopy
experiment and in the more severe tail-clip model
using hemophilia B mice. We have since produced
mammalian-expressed SerpinPC and have demon-
strated efficacy at very low doses in hemophilia A
mice (unpublished data). The safety concerns,
however, persist, and although the effect of
long-term administration of an APC inhibitor on
inflammation is difficult to predict, it is clear
that the anticoagulant and anti-inflammatory func-
tions of APC are executed by two separate pools,
circulating and EPCR-bound. The template of
SerpinPC, a1AT, does not bind to endothelial cells,
and does not affect the binding of protein C/APC1065-6251 Copyright  2017 The Author(s). Published by Wolters Kluweto EPCR. SerpinPC is therefore unlikely affect the
anti-inflammatory functions of APC, even at high
doses, but this will need to be tested in LPS-
challenged mice.
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